Top View
- Pharmacogenomic Associations Tables
- Neurokinin-1 (NK1) Receptor Antagonists and Combinations
- Functional Dyspepsia and Gastroparesis
- EMEND (Aprepitant and Fosaprepitant) RATIONALE FOR
- Preferred Drug List Drug Class Review Announcement
- Pharmacy Benefit Guide Together with CCHP PO Box 1997 - MS 6280 | Milwaukee, WI 53201-1997 Toll-Free: 1-844-201-4677 | Togethercchp.Org
- 56 Mar 2006 Produced by NHS Tayside Drug and Therapeutics Committee Medicines Advisory Group (MAG)
- Therapeutic Drug Class
- Antiemetic Studies on the NK1 Receptor Antagonist Aprepitant
- For Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Adults
- Aprepitant Drug Monograph
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- National Rules for Drug–Drug Interactions: Are They Appropriate for Tertiary Hospitals?
- Aprepitant to Control Nausea and Vomiting in the Pediatric ICU Setting
- Comparison of Antiemetic Efficacy Between Single and Repeated
- Anaphylactic Shock and Cardiac Arrest
- January 1, 2017
- The Effects of Drugs on Human Models of Emotional Processing: an Account of Antidepressant Drug Treatment Abbie Pringle, Phd; Catherine J
- Aprepitant EMEND (Aprepitant) Capsules Could Result in Elevated Plasma Concentrations of These Drugs, Initial U.S
- NCCN Guidelines Index NHL Table of Contents Discussion
- EMEND Capsules and EMEND for Oral Suspension Can Be EMEND CAPSULES and EMEND for ORAL SUSPENSION Safely Administered with Or Without Food
- Systemic Anticancer Therapy Drug Interactions Table
- EQUETRO(Carbamazepine)
- Cannabinoid Hyperemesis Syndrome: Definition, Pathophysiology, Clinical
- Effectiveness of Aprepitant in Patients with Refractory Pruritus Secondary
- SCNAUSEA Appendix
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- SCNAUSEA – Guidelines for Preventing and Treatment of Chemotherapy-Induced Nausea
- Guidelines for the Use of Anti-Emetics with Chemotherapy
- A Discussion on Managing Drug Interactions in Oncology
- 01 Stockley's Herbal Medicines Interactions PRELIMS 1
- The Neurokinin-1 Receptor Antagonist Aprepitant: an Intelligent Bullet Against Cancer?
- (NK1) Receptor Antagonist in Major Depression
- PONV Prophylaxis Guidelines
- Table [1]: Definition of Reported Outcomes Study Outcome
- AHFS Pharmacologic-Therapeutic Classification System
- EMEND, INN-Aprepitant
- Gastroparesis and Nausea
- Reference ID: 4383956
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- 209296S000lbl.Pdf
- Pdf 597.19 K
- Federal Register/Vol. 86, No. 5/Friday, January 8, 2021/Notices
- Package Leaflet: Information for the User Aprepitant 80 Mg Hard
- Guidelines on Management of Cyclic Vomiting Syndrome in Adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association
- 5-HT3 Receptor Antagonists for the Treatment of Nausea/Vomiting
- Aprepitant for Refractory Cutaneous T-Cell Lymphoma-Associated Pruritus: 4 Cases and a Review of the Literature.” BMC Cancer 17 (1): 200
- Antiemetics for Oncology – Commercial Medical Benefit Drug
- 5-HT3 Receptor Antagonists and Combinations)
- Aprepitant for the Prevention of Acute Chemotherapy- Induced Nausea and Vomiting in Children: Overcoming Barriers
- Anaphylactic Shock and Cardiac Arrest Secondary to Aprepitant
- The NK-1 Receptor-Antagonist Aprepitant in High-Dose Chemotherapy
- Emend, INN-Aprepitant